Last reviewed · How we verify
NCT04672642
Evaluation of the SpyGlass DS for Detection of Residual Pancreatic Calculations
NA trial testing SpyGlass DS in Pancreatitis, Chronic in 27 participants. Completed in 13 March 2024.
13 March 2024
Quick facts
| Lead sponsor | Hospital St. Joseph, Marseille, France |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 27 |
| Start date | 12 July 2021 |
| Primary completion | 13 March 2024 |
| Estimated completion | 13 March 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- SpyGlass DS
Conditions studied
- Pancreatitis, Chronic — all drugs for Pancreatitis, Chronic →
Sponsor
Hospital St. Joseph, Marseille, France
Who can join
18 Months and older, any sex, with Pancreatitis, Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to assess the efficacy of the SpyGlass DS for the detection of residual pancreatic calculations after endoscopic treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Management of chronic pancreatitis: recent advances and future prospects.
Han C, Lv YW, Hu LH. · · 2024 · cited 5× · PMID 38406795 · DOI 10.1177/17562848241234480
Verify or expand the search:
- PubMed search for NCT04672642
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatitis, Chronic
Currently open trials in the same condition.
- NCT07171112 — Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis · Phase 2 · recruiting
- NCT07202559 — Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Sho · NA · recruiting
- NCT06729996 — Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus · Phase 2 · recruiting
- NCT06549725 — Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pa · NA · recruiting
- NCT06330441 — Pancreatic Cancer Screening in a Population at High Risk · NA · recruiting
Other Hospital St. Joseph, Marseille, France trials
Trials by the same sponsor.
- NCT05779735 — Validation of Ultrasound "Angle of Progression" Measurement to Decrease the Cesarean Rate · NA · unknown
- NCT05662657 — Prevalence of Post Traumatic Stress Disorder Related to Diabetes Diagnosis or Severe Hypoglycaemia in Adult With Type 1 · completed
- NCT05068973 — Evaluation of the NOVATECH ® LUCIOLA TM EB Fiducial Marker During Radiotherapy Sessions in Lung Cancer Patients · NA · unknown
- NCT04945746 — Dispersion Stability · NA · active not recruiting
- NCT04839627 — Impact of Serum Progesterone Levels on the Day of Fresh and Frozen Embryo Transfer on the Ongoing Pregnancy Rates. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04672642 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital St. Joseph, Marseille, France
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04672642.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing